SG11202007508TA - Farber disease markers and uses thereof - Google Patents

Farber disease markers and uses thereof

Info

Publication number
SG11202007508TA
SG11202007508TA SG11202007508TA SG11202007508TA SG11202007508TA SG 11202007508T A SG11202007508T A SG 11202007508TA SG 11202007508T A SG11202007508T A SG 11202007508TA SG 11202007508T A SG11202007508T A SG 11202007508TA SG 11202007508T A SG11202007508T A SG 11202007508TA
Authority
SG
Singapore
Prior art keywords
disease markers
farber disease
farber
markers
disease
Prior art date
Application number
SG11202007508TA
Other languages
English (en)
Inventor
Christine Coquery
Brante Sampey
Original Assignee
Enzyvant Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzyvant Therapeutics Gmbh filed Critical Enzyvant Therapeutics Gmbh
Publication of SG11202007508TA publication Critical patent/SG11202007508TA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Obesity (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202007508TA 2018-03-27 2019-03-22 Farber disease markers and uses thereof SG11202007508TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862648775P 2018-03-27 2018-03-27
PCT/IB2019/000290 WO2019186272A1 (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Publications (1)

Publication Number Publication Date
SG11202007508TA true SG11202007508TA (en) 2020-09-29

Family

ID=66530353

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007508TA SG11202007508TA (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Country Status (15)

Country Link
EP (1) EP3775924A1 (zh)
JP (2) JP2021516757A (zh)
KR (2) KR20240111011A (zh)
CN (2) CN118112249A (zh)
AU (1) AU2019244477A1 (zh)
BR (1) BR112020016435A2 (zh)
CA (1) CA3090354A1 (zh)
CL (1) CL2020002105A1 (zh)
CO (1) CO2020010043A2 (zh)
IL (2) IL311212A (zh)
MX (1) MX2020008377A (zh)
PH (1) PH12020551206A1 (zh)
RU (1) RU2020119065A (zh)
SG (1) SG11202007508TA (zh)
WO (1) WO2019186272A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220088158A1 (en) * 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
EP0706374B1 (en) 1993-06-30 1997-12-10 Genentech, Inc. Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
WO2014160390A1 (en) * 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
EP3115786A1 (en) * 2015-07-08 2017-01-11 Centogene AG Method for the diagnosis of farber's disease

Also Published As

Publication number Publication date
JP2023159164A (ja) 2023-10-31
CA3090354A1 (en) 2019-10-03
IL311212A (en) 2024-05-01
KR20200136367A (ko) 2020-12-07
KR20240111011A (ko) 2024-07-16
AU2019244477A1 (en) 2020-06-25
JP2021516757A (ja) 2021-07-08
CO2020010043A2 (es) 2020-11-10
RU2020119065A (ru) 2022-04-27
CN111971562A (zh) 2020-11-20
CL2020002105A1 (es) 2020-12-04
WO2019186272A1 (en) 2019-10-03
PH12020551206A1 (en) 2021-04-19
EP3775924A1 (en) 2021-02-17
MX2020008377A (es) 2020-09-25
IL276420A (en) 2020-09-30
CN118112249A (zh) 2024-05-31
BR112020016435A2 (pt) 2020-12-15

Similar Documents

Publication Publication Date Title
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
SG11202101517PA (en) Isoquinoline-steroid conjugates and uses thereof
IL278142A (en) Antiproliferative compounds and their uses
EP3443861A4 (en) ARTIFICIAL NAIL AND ASSOCIATED TRANSFER MOUNTING ASSEMBLY
EP3426159A4 (en) IDENTIFICATION OF ANATOMICAL STRUCTURES
IL278881A (en) Cannabinoids and their use
SG11202009280RA (en) Compounds and uses thereof
IL277791A (en) HSP90 targeting conjugates and their formulations
PL3336196T3 (pl) Markery pszenicy i ich zastosowanie
IL279483A (en) Cyanotriazole compounds and their uses
SG11202009242RA (en) Short conjugated oligoelectrolytes and uses thereof
IL279877A (en) Ibusidanib forms and pharmaceutical preparations
GB201701480D0 (en) Disease resistance
IL276420A (en) Suburb disease markers and their uses
GB201803387D0 (en) Disease detection
IL287503A (en) Thio-semicarbazide compounds and their use
IL280369A (en) Myokines and their uses
GB201717738D0 (en) Well design and associated well structures
EP3344986A4 (en) MARKERS OF CORONARY DISEASE AND USES THEREOF
GB201803252D0 (en) Markers and uses thereof
ZA202106713B (en) Novel pathological marker and uses thereof
GB2594638B (en) Pancreas disease virus markers
GB201816605D0 (en) New formulations and uses thereof
GB201820629D0 (en) Marker
SG11202011823SA (en) Activator-nucleator formulations